Bristol-Myers Squibb Company Ce
CELG-RI · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $48,300 | $45,006 | $46,159 | $46,385 |
| % Growth | 7.3% | -2.5% | -0.5% | – |
| Cost of Goods Sold | $20,868 | $10,693 | $10,137 | $9,940 |
| Gross Profit | $27,432 | $34,313 | $36,022 | $36,445 |
| % Margin | 56.8% | 76.2% | 78% | 78.6% |
| R&D Expenses | $11,159 | $9,299 | $9,509 | $10,195 |
| G&A Expenses | $6,365 | $0 | $0 | $0 |
| SG&A Expenses | $7,865 | $7,772 | $7,814 | $7,690 |
| Sales & Mktg Exp. | $1,500 | $0 | $7,814 | $7,690 |
| Other Operating Expenses | -$1,250 | $9,047 | $9,595 | $10,023 |
| Operating Expenses | $17,774 | $26,118 | $26,918 | $27,908 |
| Operating Income | $9,658 | $8,195 | $9,104 | $8,537 |
| % Margin | 20% | 18.2% | 19.7% | 18.4% |
| Other Income/Exp. Net | -$18,037 | $245 | -$1,391 | -$439 |
| Pre-Tax Income | -$8,379 | $8,440 | $7,713 | $8,098 |
| Tax Expense | $554 | $400 | $1,368 | $1,084 |
| Net Income | -$8,948 | $8,025 | $6,327 | $6,994 |
| % Margin | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS | -4.41 | 3.88 | 2.97 | 3.15 |
| % Growth | -213.7% | 30.6% | -5.7% | – |
| EPS Diluted | -4.41 | 3.86 | 2.95 | 3.12 |
| Weighted Avg Shares Out | 2,027 | 2,069 | 2,130 | 2,221 |
| Weighted Avg Shares Out Dil | 2,027 | 2,078 | 2,146 | 2,245 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,947 | $1,166 | $1,232 | $1,334 |
| Depreciation & Amortization | $9,600 | $9,760 | $10,276 | $10,686 |
| EBITDA | $3,168 | $19,366 | $19,221 | $20,118 |
| % Margin | 6.6% | 43% | 41.6% | 43.4% |